The ongoing debate surrounding mammographic screening for breast cancer has been a persistent and divisive topic for over two decades. The crux of the disagreement lies in the trade-off between potential benefits, such as early detection leading to improved outcomes, and the drawbacks, primarily the high incidence of false-positive results and cases of overdiagnosis.

Despite these controversies, the global landscape of breast cancer has been marked by a concerning increase in both incidence and mortality due to late-stage diagnoses. Technological advancements in screening methods have added complexity to the discourse, contributing to a growing acceptance that screening can indeed extend lives.

However, as the acknowledgment of screening’s potential grows, so do the questions surrounding its implementation. The quandaries extend to issues of screening age, the targeted demographic for screening, and the optimal screening frequency. High-income countries exhibit a spectrum of approaches to breast cancer screening. In the United States, the Preventive Services Task Force recommends screening for women starting at the age of 40. Meanwhile, the Ontario Government in Canada is set to allow self-referral for publicly funded mammograms from the age of 40 starting in autumn 2024. In the UK, women between 50 and 70 are invited for screening every three years, and the European Commission’s Initiative on Breast Cancer Guidelines strongly advocates for biennial screening for women aged 50 to 69.

Despite these recommendations, breast cancer screening rates vary significantly across countries. In the European Union, Denmark boasts a high screening rate of 83%, while Bulgaria reports a notably lower rate of 21%. These discrepancies highlight the influence of local policies, healthcare infrastructure, and public awareness campaigns on screening uptake.

The global perspective on breast cancer screening becomes even more complex when considering low-income and middle-income countries (LMICs). Alarmingly, these nations face substantially low levels of screening coverage and access. The barriers include limited resources, infrastructure challenges, and insufficient awareness campaigns. The juxtaposition of high screening rates in affluent nations and dire disparities in LMICs underscores the urgent need for global efforts to address and rectify these healthcare inequalities.1

Read the full article here.

References

  1. Lancet. (2023). Breast cancer screening: one size does not fit all. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(23)00590-9

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred